Skip to main content
NTHI
NASDAQ Life Sciences

CEO Amir Heshmatpour Buys $174,795 of NTHI Stock in Open Market

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.31
Mkt Cap
$85.849M
52W Low
$3.005
52W High
$12.99
52W Position info
10% above low
Off High info
75% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

NTHI is trading near its 52-week low of $3.005 (10% above the low).

Summary

CEO Amir Heshmatpour bought $174,795 of NTHI stock in two open-market purchases on September 14-15, 2026, adding to a 90-day insider accumulation pattern.


Key Events · Ownership and Investor Activity · NTHI

  • CEO Buys $174,795 in Open Market

    Amir Heshmatpour purchased 50,000 shares across two transactions on September 14-15, 2026, at prices ranging from $3.28 to $3.96 per share.

  • Insider Accumulation Continues

    This purchase adds to a 90-day pattern of net insider buying of $578,517 with zero open-market sales, signaling ongoing insider conviction.

  • Financial Distress Context

    The company reported a going concern warning and only $2.0M in cash as of Q2 2026, making the CEO's continued personal investment a modest positive signal.


Analysis · NTHI · Life Sciences

CEO Amir Heshmatpour purchased 50,000 shares for $174,795 across two open-market transactions on September 14-15, 2026, at prices ranging from $3.28 to $3.96. This adds to a 90-day insider accumulation pattern of $578,517 in net buys with zero open-market sales. The purchase comes amid a going concern warning and only $2.0M in cash as of Q2 2026, making the CEO's continued personal investment a modest positive signal of conviction despite financial distress.

How filings like this one have moved

In the 30 days to Sep 16, 2026, 30% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NTHI was trading at $3.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.8M. The 52-week trading range was $3.01 to $12.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NTHI - Latest Insights

NTHI
Sep 10, 2026, 10:27 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.72
Real-time Price: $3.31 info
Change: -$0.405 (-11%) info
Market Cap: $85.849M info
NTHI
Sep 10, 2026, 10:25 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $3.73
Real-time Price: $3.31 info
Change: -$0.415 (-11%) info
Market Cap: $85.849M info
NTHI
Sep 09, 2026, 12:43 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.60
Real-time Price: $3.31 info
Change: -$0.290 (-8%) info
Market Cap: $85.849M info
NTHI
Aug 12, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.18
Real-time Price: $3.31 info
Change: -$1.87 (-36%) info
Market Cap: $85.849M info
NTHI
Aug 12, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.88
Real-time Price: $3.31 info
Change: -$1.57 (-32%) info
Market Cap: $85.849M info